Enovis Corp
$ 30.18
-2.20%
05 Aug - close price
- Market Cap 1,517,284,000 USD
- Current Price $ 30.18
- High / Low $ 31.10 / 30.00
- Stock P/E N/A
- Book Value 25.66
- EPS -19.27
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.54 %
- 52 Week High 34.28
- 52 Week Low 19.14
About
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$41.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-07 |
| Reported EPS | 0.76 | 0.89 | 0.95 | 0.75 | 0.79 | 0.81 | 0.98 | 0.73 | 0.62 | 0.5 | 0.79 | 0.56 |
| Estimated EPS | 0.79 | 0.81 | 0.81 | 0.65 | 0.74 | 0.74 | 0.9157 | 0.61 | 0.59 | 0.48 | 0.74 | 0.54 |
| Surprise | -0.03 | 0.08 | 0.14 | 0.1 | 0.05 | 0.07 | 0.0643 | 0.12 | 0.03 | 0.02 | 0.05 | 0.02 |
| Surprise Percentage | -3.7975% | 9.8765% | 17.284% | 15.3846% | 6.7568% | 9.4595% | 7.022% | 19.6721% | 5.0847% | 4.1667% | 6.7568% | 3.7037% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENOV
2026-08-07 04:40:54
Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The company emphasized continued execution, new product launches like the ARVIS surgical system, and a focus on profitability improvement, targeting high-teens EBITDA margins.
2026-08-06 23:40:07
Enovis Corp (ENOV) reported strong Q2 2026 earnings with 5% organic growth, driven by innovation in hips/knees and shoulders, leading to improved gross margins and positive free cash flow. Despite facing inflationary pressures and softer international markets due to geopolitical conflicts and Western European market conditions, the company reaffirmed its 2026 guidance, expecting accelerated growth in Q4 from new product launches. Management expressed confidence in continued margin expansion and cash flow improvement in 2027, attributing success to strategic product rollouts and operational efficiencies.
2026-08-06 22:40:54
Enovis is reaffirming its financial guidance for 2026. The company anticipates achieving $2.5 billion in revenue and an adjusted EBITDA margin of 23% by that year. This reiteration suggests confidence in their ongoing business strategies and growth trajectory.
2026-08-06 19:40:07
Enovis Corporation's shares fell 12.8% after reporting second-quarter earnings, despite revenue and adjusted earnings surpassing Wall Street expectations. The decline was attributed to a weaker full-year earnings per share outlook and a significant contraction in the company's adjusted operating margin, which fell 6.7 percentage points year-on-year to 4.5%. This profitability concern, coupled with broader industry fears about insurance plan changes impacting U.S. procedure growth, led to the negative investor reaction.
2026-08-06 14:40:54
This press release from Enovis announces their second-quarter 2026 financial results. The company details its performance for the quarter, providing key financial metrics and highlights. This information is crucial for investors and stakeholders to understand the company's recent operational and financial standing.
2026-08-06 13:15:54
Enovis (NYSE:ENOV) reported Q2 CY2026 sales of $582.8 million, meeting Wall Street estimates, with non-GAAP profit exceeding consensus by 6.3% at $0.90 per share. The company reaffirmed its full-year revenue and Adjusted EPS guidance. While long-term revenue growth has been a challenge, recent two-year growth and improved operating margins show some positive signs, though share dilution has impacted per-share earnings.
